Akari Therapeutics Adds Cancer Biology Expert to Scientific Advisory Board
Event summary
- Akari Therapeutics appointed Prafulla Gokhale, Ph.D., Director of the Experimental Therapeutics Core at Dana-Farber Cancer Institute, to its Scientific Advisory Board on February 26, 2026.
- Gokhale brings over 20 years of experience in preclinical oncology drug discovery and development.
- Akari's lead candidate, AKTX-101, targets the Trop2 receptor on cancer cells with a novel PH1 spliceosome-modulating payload.
- The company aims to initiate First-In-Human trials for AKTX-101 by late 2026/early 2027.
The big picture
Akari Therapeutics is positioning itself at the forefront of next-generation ADC development with a focus on RNA splicing modulation, a mechanism that could offer unique advantages in tumor cell killing and immune system engagement. The appointment of Prafulla Gokhale underscores the company's commitment to leveraging cutting-edge scientific expertise to drive its clinical programs forward. As the oncology biotechnology sector continues to evolve, Akari's differentiated approach could attract significant attention from investors and partners.
What we're watching
- Clinical Development
- The pace at which Akari advances AKTX-101 toward First-In-Human trials will determine its competitive positioning in the ADC space.
- Scientific Leadership
- How Prafulla Gokhale's expertise in RNA biology and translational oncology will influence the design and execution of AKTX-101's clinical strategy.
- Market Differentiation
- Whether Akari's novel PH1 spliceosome-modulating payload can deliver superior efficacy and immune activation compared to conventional ADC payloads.
Related topics